|

Nadofaragene Firadenovec Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: ADSTILADRIN, Adstiladrin

Pipeline

Phase 3: 3

Top Sponsors

  • Ferring Pharmaceuticals2
  • Memorial Sloan Kettering Cancer Center1

Indications

  • Cancer3
  • Intermediate Risk Non-Muscle Invasive Bladder Cancer1
  • Non-muscle Invasive Bladder Cancer With Carcinoma in Situ1
  • Non-Muscle Invasive Bladder Cancer1

Mobile, Alabama1 trial

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

University of South Alabama (USA) Health System - USACM

Phase 3

Los Angeles, California1 trial

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

American Institute of Research

Phase 3

New York, New York1 trial

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.